Induction of Bnabs: How and When Will We Get There?
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
IAVI & Partners' Presentations at HIV R4P 2016
Main Program Highlights Protection from Rectal SHIV Infection Induced by Mucosal Vaccination with a Replication-competent VSV-HIV Chimera Delivering Env Trimers (Symposium Presentation) Date: Tuesday, 18 October Time: 15:52-16:14 Venue: Sheraton Grand Chicago, Chicago Ballroom VI-VII Chairs: Bonnie Mathieson, Office of AIDS Research; Etienne Karita, Projet San Francisco Presenter: Chris Parks, IAVI AAV and Other Novel Antibody Delivery Platforms (Symposium Presentation) Date: Wednesday, 19 October Time: 16:14-16:36 Venue: Sheraton Grand Chicago, Sheraton Ballroom IV-V Chairs: Magdalena E Sobieszczyk, College of Physicians and Surgeons, Columbia University; Glenda Gray, South African Medical Research Council Presenter: Frances Priddy, IAVI When We Got It Right and When We Got It Wrong (Round Table Presentation) Date: Thursday, 20 October Time: 8:30-8:40 Venue: Sheraton Grand Chicago, Chicago Ballroom VIII-X Chair: Mitchell Warren, AVAC Presenter: Maggie Keane, IAVI For full program details go to: http://www.iavi.org/events/599-hivr4p-2016 Satellite Symposium HIV Vaccine Design and Development Partnerships in Africa: Showcasing African-led Basic HIV Prevention Science Research Monday 17 October 2016, 8:30 - 12:30 Sheraton Grand Chicago, Chicago Ballroom IX Refreshments provided This session will bring together African and international scientists, policy makers, advocates and institutions involved in HIV prevention research. They will take a look at current design and development partnership models to identify success factors, gaps and opportunities for enhanced collaborations, as well as young scientists. Presenters and participants will be invited to share their ideas of the next priorities for African HIV prevention research. These will be discussed in a panel discussion on the way forward. -
HIV Vaccines: from Prevention to Cure
2017 UCSF‐Gladstone CFAR Research Symposium Friday, May 19, 2017 – Mission Bay Conference Center HIV Vaccines: From Prevention to Cure 8:00‐9:00 Breakfast 9:00‐9:05 Welcome and Introductions 9:05‐10:00 Prevention Keynote: Mark Feinberg, MD, PhD HIV Vaccine Development: How will we President and CEO translate scientific opportunity into International AIDS Vaccine Initiative public health impact? 10:00‐10:40 Human Monoclonal Antibodies for Pre‐ John R. Mascola, MD Exposure Prophylaxis (PrEP) of HIV‐1 Director of the Dale and Betty Bumpers Vaccine Research Center Infection National Institute of Allergy and Infectious Diseases (NIAID) National Institutes of Health 10:40‐11:20 Progress in Advancing Vaccine Concepts Julie McElrath, MD, PhD to P5 Efficacy Trials Senior Vice President and Director Vaccine and Infectious Disease Division Member, Vaccine and Infectious Disease Division Member, Clinical Research Division Fred Hutchinson Cancer Research Center Professor of Medicine Adjunct Professor of Pathobiology, Global Health, and Laboratory Medicine, University of Washington 11:20‐12:00 Defining Correlates of Protection against Galit Alter, PhD HIV/SIV Associate Professor of Medicine Samana Cay MGH Research Scholar Director, Ragon Institute Imaging Core Director, Harvard Center for Aids Research Immunology Core Harvard University 12:00‐1:00 Lunch 1:00‐1:40 Ad26 Based Vaccines for HIV and Beyond Dan H. Barouch, MD, PhD Professor of Medicine Harvard Medical School Director, Center for Virology and Vaccine Research Beth Israel Deaconess Medical -
Download Program (PDF) Sunday, 21 October 2018 SA02, New Pieces To
HIVR4P 2018, HIV Research for Prevention 2018, Madrid, Spain, 21 - 25 October 2018 Download Program (PDF) Sunday, 21 October 2018 Satellites 08:45 - 12:00 Estrasburgo SA02, New Pieces to the HIV-1 Vaccine Puzzle: Germline Targeting Strategies and Immunization Protocols to Elicit Anti-HIV-1 bNAbs Hosted by: The Rockefeller University It is becoming evident that the design of a vaccine that elicits broadly protective antibodies against HIV-1 will require a meticulous engineering process to generate suitable germline targeting strategies that activate bNAb precursors and subsequently support antibody maturation in germinal centers. Encouraging results were obtained in a bNAb knock-in mouse model in which PGT121-like antibodies were elicited by step-wise immunization. Despite multiple efforts, these results have not been fully reproduced in wild type (wt) animal models with a polyclonal B cell repertoire. One of the hurdles to overcome in wt animals is the activation of bNAb precursors that are present in low frequencies. Recent studies have shown that high-affinity immunogens are necessary to efficiently activate and expand low-frequency bNAb precursors. An additional barrier for vaccine design in a wt system is the polyclonal nature of the antibody response. It is believed that immunogen refinement is necessary in order to focus the antibody response towards neutralizing epitopes and avoid distracting responses to non-neutralizing epitopes that could frustrate bNAb maturation by competition in the germinal centers. In this session, we will present progress achieved in the design of strategies to specifically activate and increase the frequency of bNAb precursors, as well as the results of immunization experiments aiming to elicit anti-HIV-1 bNAbs in wt animal models. -
IAS Durban Talk Lcorey July 19 Final Version
Progress in the HIV Vaccine Field Larry Corey, MD Principal Investigator, NIAID supported HIV Vaccine Trials Network (HVTN) Past President and Director, Fred Hutchinson Cancer Research Center Professor, Laboratory Medicine and Medicine, University of Washington Seattle, Washington USA Disclosures • None Acknowledgements • HVTN as an organization, especially my colleagues: Scott Hammer, Glenda Gray, Julie McElrath, Peter Gilbert, Jim Kublin and Susan Buchbinder • The HVTN’s major pharmaceutical and institutional collaborators: Sanofi, GSK, Janssen, VRC, IAVI and CHAVI programs • The HVTN’s community members and advisory boards • Its funders: NIAID and BMGF Special Acknowledgement Tony Fauci, MD HIV: Still the World’s Most Important Global Health Problem • US still over 45,000 new cases yearly • Globally more than 2 million new infections occur per year • Number of people living with HIV increasing yearly • Long way from an AIDS Free Generation Indiana HIV outbreak: geographic distribution Scott County pop. 24,000; Austin, IN pop. 4,200 Adams, NEJM 2015;373:1379-1380 Scott County Commentary on HIV Prevention Strategies • While many prevention strategies have high efficacy in clinical trials, their extended effectiveness requires continuous adherence, which often results in decreased effectiveness over time. • They also require high saturation in a community and hence their long term effects on population based incidence in country’s with generalized epidemics is uncertain: • Condoms; PrEP; vaginal rings; PEP; circumcision, all deserve support and increased uptake • Test and Treat very effective for the individual; eventual population effect will be achieved The Need for an HIV Vaccine • With asymptomatic acquisition, prolonged subclinical infection, and sexual transmission, getting to an AIDS Free Generation will require a vaccine. -
Capturing Participant Data for Mucosal Sample Interpretation: a Guide for HIV Investigators
Cover photographs of mucosal tissues kindly provided by: • Ann Marie Carias and Thomas J. Hope (Northwestern University), US (top right, ectocervical tissue) • Kimberly Smythe and Nicole Frahm (HVTN/FHCRC) and Kim Melton (FHCRC), US (bottom left, rectal tissue) Back cover photographs kindly provided by: • Kimberly Smythe and Nicole Frahm (HVTN/FHCRC), US (top right, rectal tissue) • Ann Marie Carias and Thomas J. Hope (Northwestern University), US (bottom left, vaginal tissue) How to cite this Guide: Capturing Participant Data for Mucosal Sample Interpretation: A Guide for HIV Investigators. Published by the Global HIV Vaccine Enterprise with the support of the National Institute of Allergy and Infectious Diseases (NIAID) and the HIV Mucosal Immunology Group (MIG). Second edition, March 2016. Organizing Committee: Mary Gross (Fred Hutchinson Cancer Research Center, FHCRC); Patricia D’Souza (NIAID); Amapola Manrique & Yegor Voronin (Global HIV Vaccine Enterprise). To order copies: Global HIV Enterprise 64 Beaver street, # 352 New York, NY 10004, US Email: [email protected] The online version is available at: www.vaccineenterprise.org/mucosal-sampling-guide Capturing Participant Data for Mucosal Sample Interpretation: A Guide for HIV Investigators 2 N D E D I T I O N | A P R I L 2016 Acknowledgments The Global HIV Vaccine Enterprise, the National Institute of Allergy and Infectious Diseases (NIAID), and the HIV Mucosal Immunology Group (MIG) gratefully acknowledge the contributions of the many experts who responded to requests for concepts, content, references, and comments. We would like to thank them for the practical and essential feedback they provided on prior drafts of the document. Notable contributors are listed here in alphabetic order: Maria L Alcaide (University of Miami Miller School of Medicine), Michele Andrasik (University of Washington, HIV Vaccine Trials Network (HVTN)); Peter Anton (University of California, Los Angeles); Chuka Anude (Henry M.